Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that human pilot study #2, GLP-1-H24-2, (the "Study") is underway and the first dosing visit for all nine study participants has already concluded.The Study is a three-arm, crossover investigation that will compare three 7 mg semaglutide dose formulations:a positive control Rybelsus® swallowed tablet (already...
Read more








